The biotech sector, as measured by the XBI ETF, fell more than 2% during the current trading session, moving in sympathy with a broader market downturn. The negative sentiment appears to be driven by a sell-off in technology and other growth-oriented stocks following the highly anticipated IPO of AI company Anthropic. There is no clear, sector-specific negative catalyst for biotech today; the move is consistent with the general risk-off tone in the market as investors take profits.